Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Andrew Berens upgraded Blueprint Medicines (BPMC) from Underperform to Market Perform and increased the price target from $50 to $97.
May 06, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines was upgraded by Leerink Partners from Underperform to Market Perform, with a price target increase from $50 to $97.
The upgrade from Underperform to Market Perform by a reputable analyst, along with a significant increase in the price target, suggests a positive outlook for Blueprint Medicines. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100